Introduction {#s1}
============

Accurate determination of cause of death is challenging in patients with chronic obstructive pulmonary disease (COPD) because of the high comorbidities and complex clinical scenarios at the time of death. Consistent attribution of cause of death is important in all clinical trials, especially when mortality is an outcome measure and causes of death are of interest. The TIOtropium Safety and Performance In Respimat (TIOSPIR) trial \[[@C1]\] was conducted to clarify a potential risk for increased death with tiotropium Respimat, because a higher number of deaths was observed in studies with tiotropium Respimat *versus* placebo, albeit on a limited number of deaths \[[@C1]--[@C3]\]. However, tiotropium HandiHaler was associated with a lower probability of death *versus* placebo in the 4 year Understanding the Potential Long-term Impacts on Function with Tiotropium (UPLIFT) study as well as in the overall HandiHaler database \[[@C4], [@C5]\]. As the imbalance in the Respimat studies appeared to be prominent in patients with arrhythmias at study entry, cardiovascular deaths, including sudden (cardiac) deaths, were of special interest for two main reasons. First, sudden deaths are not always caused by cardiac disease \[[@C6]\], despite often being mislabelled as such and despite evidence that patients with COPD are at increased risk of sudden cardiac death. Second, sudden death presents unique difficulties because it commonly occurs outside the hospital and is frequently unwitnessed \[[@C7], [@C8]\].

Similar to the UPLIFT trial \[[@C4], [@C9]\], a mortality adjudication committee (MAC) was established in TIOSPIR to provide a systematic, independent, blinded assessment of cause-specific mortality reported by the investigators. We therefore undertook a *post hoc* analysis of the data on mortality and attributed causes of death in the TIOSPIR trial.

Here, we describe the process of mortality adjudication in the TIOSPIR trial and compare investigator-reported *versus* adjudicated results for system organ class (SOC) and specific causes of death of interest, with a specific focus on cardiovascular death, including sudden death. In particular, we aimed to evaluate the impact of a standardised adjudication process on the assessment of cause-specific mortality.

Materials and methods {#s2}
=====================

TIOSPIR study design {#s2a}
--------------------

The TIOSPIR study was a randomised, double-blind, parallel-group trial (17 135 patients with COPD) comparing the safety and efficacy of tiotropium Respimat 2.5 or 5 μg *versus* tiotropium HandiHaler 18 μg. The primary safety end-point was time to all-cause mortality. Other outcome measures included time to first major adverse cardiovascular event (MACE), which comprised stroke, myocardial infarction (MI), sudden death, cardiac death, sudden cardiac death and fatal event in the SOCs for cardiac and vascular disorders \[[@C1], [@C3]\].

The trial was performed in accordance with the Declaration of Helsinki, and the study protocol and procedures were approved by relevant institutional review boards and ethics committees, as described previously \[[@C1]\]. All patients provided written informed consent.

MAC documentation and adjudication processes in the TIOSPIR study {#s2b}
-----------------------------------------------------------------

Adverse events were triaged by medical doctors (medical reviewers/event monitors) and reviewed in priority order for completeness and medical consistency before sending to MAC (supplementary material).

The MAC comprised three pulmonologists (including the chair of the MAC), three cardiologists, an oncologist and a general medicine member (internist). A set of questions was developed for the medical reviewers/event monitors as a resource for the investigational sites to maximise information from patients who initially presented with no or minimal information. The objective of the MAC was to provide continuous, systematic, independent, blinded, expert assessment of investigator-reported deaths. The MAC assigned a single primary cause of death coded to preferred term level using the Medical Dictionary for Regulatory Activities (MedDRA) according to specific rules devised for the TIOSPIR trial within their principles of operation (supplementary material), which also incorporated many of the general principles and methods generally used in the classification of primary cause of death. However, the site investigators were not made aware of the principles of operation utilised by the MAC \[[@C10]\]. A quality control process evaluated the reliability of the adjudication process (supplementary material).

Based on definitions by the World Health Organization, the American College of Cardiology and the American Heart Association \[[@C11]--[@C13]\], the MAC defined sudden cardiac deaths as those occurring within 1 h of an abrupt change of a person\'s clinical state without other obvious non-cardiac cause, while sudden death referred to deaths occurring more than 1 h but less than 24 h after the patient was last observed alive and without evidence of a deteriorating medical condition. The site investigators did not have access to the principles of operation utilised by the MAC.

Statistical analysis {#s2c}
--------------------

Concordance and discordance between investigator-reported and MAC-adjudicated causes of death (SOC and preferred term) were assessed using shift tables. Given that the analysis was not treatment-related, data from the three treatment arms were pooled.

Additionally, a sensitivity analysis of MACE, including the term "death unknown", was performed. Investigator-reported and MAC-adjudicated fatal events of MACE and its individual components were compared for the tiotropium Respimat 5 µg and HandiHaler 18 µg treatment groups using rate ratios.

Results {#s3}
=======

Numbers of deaths and autopsies {#s3a}
-------------------------------

Vital status at the conclusion of the trial was ascertained in 99.7% of participants. There were 1302 deaths: 440 in the tiotropium Respimat 2.5 μg group, 423 in the Respimat 5 μg group and 439 in the tiotropium HandiHaler 18 μg group. Although about 382 autopsies were performed, their results were frequently not available for review and, in many cases, were uninformative.

Causes of death {#s3b}
---------------

The classification by SOC of investigator-reported *versus* MAC-adjudicated cause of death as a percentage of deaths is summarised in [figure 1](#F1){ref-type="fig"}. The three leading causes of death, at the SOC level, according to both the investigators and the MAC, were respiratory, neoplasm and general ([figure 1](#F1){ref-type="fig"}, table S1). However, there were notable differences in the number of deaths attributed to each of the SOC categories by the MAC compared with the investigators ([figure 1](#F1){ref-type="fig"}, table S1). Differences were especially marked for the cardiac deaths SOC, where the number of deaths was higher when investigator-reported (n=214; 16.4%) than when MAC-adjudicated (n=66; 5.1%). On the other hand, deaths due to general disorders and neoplasms were higher when MAC-adjudicated (n=320; 24.6% and n=305; 23.4%, respectively) than when investigator-reported (n=226; 17.4% and 249; 19.1%, respectively). The number of deaths due to respiratory causes was also higher when MAC-adjudicated (n=369; 28.3%) than when investigator-reported (n=326; 25.0%) (table S1). There was agreement (concordance), at the SOC level, of the MAC-adjudicated cause of death with the investigator-reported cause of death in 904 of 1302 (69.4%) cases. Concordance was highest for cancer-related deaths (neoplasms) (247 of 249 cases, 99.2%). However, due to the "cancer rule" (supplementary material), the MAC found 58 additional cancer cases, of which 23 were assigned MedDRA terms for lung cancer. Concordance was lowest for cardiac deaths: just 58 of the 214 cases (27.1%). Of the 156 discordant cases, 74 (47.4%) were adjudicated to sudden death or sudden cardiac death, 36 to respiratory (23.1%), 11 to neoplasm (7.1%), 10 to infections (6.4%) and the remaining 6 cases to other causes (3.9%), while 19 were identified by the investigator as cardiorespiratory arrest (n=6), cardiopulmonary failure (n=8) or *cor pulmonale* (n=5). Moreover, of the 36 cases initially determined as cardiac by the investigator, but adjudicated to respiratory by the MAC, 33 were assigned COPD as the specific cause of death by the MAC.

![Classification of investigator-reported and MAC-adjudicated causes of death, as a percentage of patients with death by system organ class (SOC). MAC: mortality adjudication committee.](00073-2016.01){#F1}

Discordance was high for the SOC category of infections (70 of 148 (47.3%)) and respiratory deaths (63 of 326 cases (19.3%)) (table S1), although discordance in the SOC respiratory was much less than in SOC cardiac (156 of 214 (72.9%)). Thirty-one (49.2%) of the discordant respiratory cases were assigned to general, which includes sudden cardiac death (n=9) or sudden death (n=12), by the MAC; another 16 cases to cancer (lung neoplasm malignant, small-cell lung cancer, lung cancer metastatic); and 6 cases to infection (pneumonia). On the other hand, the MAC reassigned 36 cardiac deaths, 30 general deaths and 33 infections deaths to respiratory causes, with 96 of these 99 cases assigned to the preferred term COPD.

Detailed assessment of cardiac deaths focused on just the investigator-reported cases of fatal MI (n=46), comprising the specific diagnoses acute MI/MI, post-procedural MI and acute coronary syndrome ([table 1](#TB1){ref-type="table"}). The MAC-adjudicated cause of death, comprising seven specific diagnostic terms, was concordant in 21 of 46 cases (45.7%). The two main reasons for the differences in assignment of cause of death between investigators and adjudicators were that the MAC protocol required that the underlying cause of death be recorded and that specific documentation be cited in order to assign certain causes of death. In four cases where there was discordance between an investigator-reported fatal MI and the adjudicated cause of death, an underlying cause of death (*e.g.* aortic aneurysm, brain neoplasm or COPD) was provided. In 21 cases, insufficient documentation was available to assign an underlying cause of death, leading to the assignment of a more general term (death, sudden death or sudden cardiac death).

###### 

Comparison of investigator-reported fatal myocardial infarction (MI)^\#^ with adjudicated terms

                                **Causes of death by MAC**                           
  ----------------------------- ---------------------------- --- --- --- --- --- --- ----
  **Acute MI/MI**               21                           1   1   1   4   8   6   42
  **Post-procedural MI**                                     1                       1
  **Acute coronary syndrome**                                                1   2   3
  **Total**                     21                           2   1   1   4   9   8   46

MAC: mortality adjudication committee. ^\#^: MI is SMQ (standardised MedDRA query) ischaemic heart disease, sub-SMQ MI. ^¶^: there was insufficient information/evidence for the MAC to assign a specific underlying cause of death so the categorical assignment was made based on MAC protocol-defined criteria. Sudden cardiac deaths were those occurring within 1 h of an abrupt change of a person\'s clinical state without other obvious non-cardiac cause, and sudden death refers to those occurring more than 1 h but less than 24 h of the patient last being observed alive and without evidence of a deteriorating medical condition. "Death" refers to unexplained death.

Sensitivity analysis {#s3c}
--------------------

The composite end-points of fatal MACE and fatal MACE plus unknown death showed similar numbers of investigator-reported and MAC-adjudicated deaths for the tiotropium Respimat 5 µg and HandiHaler 18 µg treatment groups ([figure 2](#F2){ref-type="fig"}). Incidence rates for the individual components within these composites, including sudden death and sudden cardiac death, were also similar, with the 95% CI of most of the rate ratios including 1. However, although numbers were very small, there was a between-treatment difference for MAC-adjudicated MI deaths: more deaths were attributed to MI in the tiotropium Respimat group than in the HandiHaler group (n=11 *versus* 3; rate ratio (95% CI) 3.64 (1.02‒13.06) for tiotropium HandiHaler 18 µg *versus* tiotropium Respimat).

![Comparison of investigator-reported and mortality adjudication committee-adjudicated fatal events (myocardial infarction, sudden death, sudden cardiac death and death) in the tiotropium Respimat 5 µg and HandiHaler 18 µg treatment groups. IR: incidence rate per 100 patient-years; MACE: major cardiovascular event; SOC: system organ class; PV: pharmacovigilance term; PT: preferred term; ^\#^: standardised MedDRA query (SMQ) ischaemic heart disease, sub-SMQ myocardial infarction.](00073-2016.02){#F2}

Discussion {#s4}
==========

Reliable reporting of causes of death in clinical trials is essential to ensure the safety of medicines. However, it can be difficult to accurately determine cause of death in patients with COPD due to the presence of comorbidities and the tendency of attributing sudden death, especially when unwitnessed, to a cardiac cause \[[@C14]\]. Studies have concluded that a MAC \[[@C9]\] (or a clinical end-point committee) \[[@C14]\] can provide reliable, standardised adjudication of COPD mortality, which may differ from investigator-assessed cause of death. Moreover, the quality control exercise used to assess the reliability of adjudicated cardiovascular causes of death within the TIOSPIR trial exceeded the target, with a proportion agreement of 94% ("almost perfect"), confirming the reliability and reproducibility of the assignment. This level of reproducibility cannot be expected by investigator assessments, as noted in this study, although investigators had access to the same level of information as the MAC.

Here, we have shown that discordance between investigator-reported and MAC-adjudicated causes of death exists, in particular for cardiovascular deaths, with investigators attributing more deaths to cardiac causes (SOC) than the MAC, and the MAC assigning more to sudden death and sudden cardiac deaths (both categorised as general disorders SOC by MedDRA). The inclusion of sudden death in general *versus* cardiovascular SOC could be a reason for the shift in attribution from cardiovascular to general disorders SOC in the MAC-adjudicated *versus* investigator-reported causes of death. The difference between the number of MAC-adjudicated and investigator-reported cases of cardiac death in the UPLIFT trial was similar to that reported here for TIOSPIR; in both trials there was a three-fold greater incidence of investigator-reported cardiac deaths \[[@C9]\].

Moreover, the MAC shifted 58 deaths from other categories to cancer as the underlying cause of death. This is due to the MAC policy that deaths of all patients with incurable cancers should be attributed to the cancer, regardless of the terminal event, which may have been related to secondary complications of the cancer or treatment for the cancer. There was also a shift from general, infectious and cardiovascular causes to respiratory, largely due to the policy that all patients whose terminal illness was initiated by a COPD exacerbation should have the death attributed to respiratory, regardless of the terminal event, which may have been pneumonia, sepsis, MI or sudden death. Thus, although MAC adjudication changed the attribution of cause of death in the TIOSPIR study in just over 30% of cases, this resulted primarily from attribution of death to the underlying cause of the terminal illness (*e.g.* COPD) rather than the immediate cause of death (*e.g.* MI).

In the Towards a Revolution in COPD Health (TORCH) study, causes of death were adjudicated by a three-physician clinical end-point committee \[[@C14]\]. Because there were no generally agreed definitions, they developed their own set of working definitions for categories of death in a COPD clinical trial population. Based on this experience, several modifications were recommended for future clinical trials of COPD mortality, including the suggestion that sudden death should be considered as a separate entity, rather than one linked necessarily to a cardiovascular cause \[[@C14]\]. Therefore, adjudication in TIOSPIR used the MedDRA classification. The apparent preferential categorisation of a COPD death as cardiac by investigators in the TORCH, UPLIFT and TIOSPIR studies may also reflect a general tendency of investigators to report the mechanism of death (such as MI), rather than the underlying cause of death. Cause of death is often attributed to MI when the actual cause of death is unknown. This could be reflected in the tendency of medical examiners to label sudden deaths as MI. In fact, sudden cardiac death is usually overestimated. Previous studies have confirmed that pre-existing coronary heart disease or congestive heart failure increase the risk of sudden death \[[@C15]--[@C17]\] and account for almost 75% of sudden cardiac deaths in the western world \[[@C18]--[@C20]\]. It is noteworthy that the deaths classified as sudden cardiac are often non-cardiac \[[@C21]\] and a significant proportion of out-of-hospital cardiac arrests in COPD patients is attributable to underlying lung disease \[[@C22]\]. Likewise, a study by H[uiart]{.smallcaps} *et al*. and the Rotterdam study emphasised that COPD was associated with an increased risk of sudden cardiac death \[[@C8]\] and a two- to three-fold higher risk of cardiovascular disease, thereby contributing to almost 50% of deaths \[[@C8], [@C23]\]. Although the MAC distinguished between sudden cardiac death (last seen alive within 1 h), sudden death (last seen alive between 1 and 24 h) and death (last seen alive \>24 h ago), these distinctions may depend more on the circumstances of death than the actual cause of death and therefore are not useful distinctions. Moreover, death that occurs more than 1 h and less than 24 h from last being seen clinically stable should not routinely be assigned to a cardiac cause, especially in a study of COPD patients, because of the likelihood that a non-trivial percentage of these cases will be determined to have had a respiratory cause of death \[[@C6], [@C24]\].

An analysis of data from death certificates from England and Wales (1993--1999) reported that using the immediate cause of death underestimates the contribution of obstructive lung disease to mortality \[[@C24]\]. This was supported by a TORCH death certificate analysis, which found that COPD was often not mentioned \[[@C25]\]. In contrast, in death certificates that mention MI, it was the underlying cause in 94% of cases \[[@C26]\]. Although this difference did not alter the interpretation of the between-treatment analyses in the UPLIFT trial, such discrepancies could potentially alter the interpretation of a clinical trial in which there was a smaller difference between treatment arms. In TIOSPIR, there were more deaths attributed to MI by the MAC in the tiotropium Respimat arm than in the HandiHaler arm (11 *versus* 3). This difference arose because there were a larger number of cases in the tiotropium Respimat arm for which sufficient data were available to actually make the diagnosis of MI according to the MAC rules (such as electrocardiogram results and cardiac enzyme levels), whereas this was less often the case in the HandiHaler arm. This between-treatment result was not observed when all cardiovascular deaths (fatal MACE) were considered, or when proportions of sudden deaths and sudden cardiac deaths were compared, demonstrating the usefulness of composite MACE end-points. For periods up to 48 weeks, tiotropium maintenance therapy administered using Respimat or HandiHaler once daily was not associated with an increased risk of cardiac arrhythmia in patients with COPD \[[@C27]\]. Furthermore, mortality and subsequent cardiac events were not increased *versus* placebo in the UPLIFT trial in patients with an acute arrhythmia event \[[@C28]\].

Death may be the end result of a complex series of sequential and contemporaneous factors. Therefore, attributing a single cause of death is often artificial. However, attributing death to the final illness is both logical and leads to consistency of adjudication. Unknown cause of death will always remain an issue in some cases, either because there is a lack of source documentation to assign a definitive cause or because the cause is genuinely unknown despite adequate documentation. In addition, the multiple comorbidities present in most COPD patients make the assignment of a single cause of death particularly difficult. These limitations with respect to assigning a specific cause of death suggest that the results of the MAC adjudication process, while reliable, may not be accurate if documentation is not available. Moreover, adjudication of the underlying cause of death may underestimate the relevance of factors contributing to the immediate cause of death. Therefore, small differences in cause-specific deaths in COPD clinical trials should be interpreted with caution. Although the approach outlined in this study provides for a consistent and reliable ascertainment of cause of death for studies of COPD, it should be noted that this approach may not be applicable for all clinical trials. Furthermore, we suggest that study coordination staff and investigators should be trained to scrutinise the nature and timing of events preceding an unexpected sudden death for future trials.

The findings from this study confirm the value of using all-cause mortality and composite cardiovascular end-points in COPD trials, such as MACE, grouping specific causes of death like sudden (cardiac) death, rather than cause-specific mortality as an outcome in COPD trials, given the difficulty in ascertaining a reliable cause of death in individual cases.
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